ArticleScientific reports2026
Comparison of capillary microsampling and venous blood for multi-pathogen serosurveillance.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Serosurveillance for vaccine-preventable diseases (VPDs) can inform public health strategies by identifying gaps in immunization programs. However, venous blood sampling, though reliable and sensitive for serosurveillance, presents logistical challenges in resource-limited settings. Capillary microsampling using dried blood spots (DBS) offers a simpler, less invasive alternative that reduces cold-chain and personnel requirements. This study evaluated the performance and stability of DBS collected on filter paper and Mitra microsamplers compared with venous plasma. IgG antibody levels against diphtheria, tetanus, pertussis, measles, mumps, rubella, and varicella were quantified using a validated fluorescent bead-based multiplex immunoassay. At baseline, strong agreement was observed between DBS and plasma, with ≥ 93% of observations within the 95% limits of agreement. Sensitivity was high (≥ 95.8%) for all pathogens except pertussis (72.2-77.8%). For DBS stored at - 20 °C with desiccants, agreement remained high at 90 days, with gradual declines observed beyond one year. At room temperature, IgG levels declined, with sensitivity ≥ 91.2% at 7 and 30 days but dropping below 90% by 90 days for several analytes. Beyond one year, IgG recovery was minimal, with sensitivity < 50% for most pathogens. These findings support DBS utility for VPD serosurveillance, with stability up to 90 days at - 20 °C and 30 days at room temperature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.